Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.81 |
| ▸ | PKM | P14618 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14133539 | 0.76 | ALDH1A1 (0.75) | ALDH1A1KMT2APKMMEN1KDM4E | |
| SCHEMBL14133355 | 0.75 | KDM4E (0.74) | ALDH1A1PKMKDM4ERAB9AMAPT | |
| SCHEMBL14134055 | 0.71 | KDM4E (0.64) | ALDH1A1KMT2APKMMEN1LMNA | |
| SCHEMBL14133536 | 0.70 | PKM (1.00) | ALDH1A1KMT2APKMMEN1LMNA | |
| SCHEMBL14133533 | 0.70 | KDM4E (0.71) | ALDH1A1KMT2APKMMEN1LMNA | |
| SCHEMBL9993451 | 0.70 | ALDH1A1 (0.53) | ALDH1A1KMT2APKMMEN1LMNA | |
| SCHEMBL23052318 | 0.70 | ALDH1A1 (0.70) | ALDH1A1KMT2APKMMEN1LMNA | |
| SCHEMBL23052081 | 0.70 | ALDH1A1 (0.70) | ALDH1A1KMT2APKMMEN1LMNA | |
| SCHEMBL14133805 | 0.69 | KDM4E (0.71) | ALDH1A1KMT2APKMMEN1LMNA | |
| SCHEMBL23052359 | 0.68 | ALDH1A1 (0.72) | ALDH1A1KMT2APKMMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354327-A1 | COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF | CYTUS H&B CO LTD (KR) | 2020-11-12 | — | — | US | disclosed |
| US-20200354327-A1 | COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF | CYTUS H&B CO LTD (KR) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354327-A1 | COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF | STAT3, JAK2, STAT6 | ALDH1A1 1603/4885KMT2A 608/4885PKM 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.